InflaRx N.V. (NASDAQ:IFRX) Given Consensus Rating of "Moderate Buy" by Brokerages

Key Points

• InflaRx has a “Moderate Buy” consensus rating from eight analysts, with four buys, two strong buys, one hold and one sell. The average 12-month price target is $7.33, well above the reported share price of $2.10.
• Institutional ownership stands at 42.39%, with several funds increasing their positions; Montanova Capital expanded its stake by 15 million shares in the second quarter.
• InflaRx reported a quarterly loss of $0.11 per share, missing the $0.07 consensus estimate, while analysts expect a full-year loss of $0.31 per share. The company is developing vilobelimab, an experimental therapy targeting inflammatory diseases through the C5a pathway.

Shares of InflaRx N.V. (NASDAQ:IFRX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight research firms that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $7.3333.

A number of research firms have recently weighed in on IFRX. Weiss Ratings restated a "sell (d-)" rating on shares of InflaRx in a research report on Wednesday, June 24th. HC Wainwright lifted their price objective on InflaRx from $6.00 to $8.00 and gave the stock a "buy" rating in a research report on Monday, May 11th. Wall Street Zen raised InflaRx from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. Cantor Fitzgerald upped their target price on shares of InflaRx from $4.00 to $6.00 and gave the company an "overweight" rating in a research report on Friday, August 7th. Finally, Raymond James Financial raised shares of InflaRx from an "outperform" rating to a "strong-buy" rating and raised their target price for the company from $7.00 to $9.00 in a research note on Wednesday, May 13th.

Hedge Funds Weigh In On InflaRx

Hedge funds and other institutional investors have recently bought and sold shares of the business. 683 Capital Management LLC lifted its stake in InflaRx by 47.3% in the fourth quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company's stock valued at $3,348,000 after buying an additional 1,065,000 shares during the period. T3 Companies LLC acquired a new position in shares of InflaRx during the 4th quarter worth about $294,000. DCF Advisers LLC acquired a new position in shares of InflaRx during the 4th quarter worth about $160,000. Concurrent Investment Advisors LLC increased its stake in shares of InflaRx by 56.9% in the 4th quarter. Concurrent Investment Advisors LLC now owns 52,951 shares of the company's stock valued at $53,000 after acquiring an additional 19,200 shares during the last quarter. Finally, Montanova Capital LLC increased its stake in shares of InflaRx by 189.1% in the 2nd quarter. Montanova Capital LLC now owns 22,933,910 shares of the company's stock valued at $51,372,000 after acquiring an additional 15,000,000 shares during the last quarter. 42.39% of the stock is owned by institutional investors.

InflaRx Price Performance

Shares of NASDAQ:IFRX opened at $2.10 on Monday. The business's fifty day moving average price is $1.93 and its two-hundred day moving average price is $1.61. InflaRx has a fifty-two week low of $0.80 and a fifty-two week high of $2.95. The stock has a market capitalization of $309.47 million, a price-to-earnings ratio of -3.62 and a beta of 2.48.

InflaRx (NASDAQ:IFRX - Get Free Report) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.11) EPS for the quarter, missing analysts' consensus estimates of ($0.07) by ($0.04). Research analysts expect that InflaRx will post -0.31 EPS for the current fiscal year.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company's lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source